HK1210177A1 - Dihydroxypyrimidine carbonic acid derivatives and their use in treatment, amelioration or prevention of a viral disease - Google Patents
Dihydroxypyrimidine carbonic acid derivatives and their use in treatment, amelioration or prevention of a viral disease Download PDFInfo
- Publication number
- HK1210177A1 HK1210177A1 HK15111131.0A HK15111131A HK1210177A1 HK 1210177 A1 HK1210177 A1 HK 1210177A1 HK 15111131 A HK15111131 A HK 15111131A HK 1210177 A1 HK1210177 A1 HK 1210177A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- optionally substituted
- alkyl
- aryl
- cycloalkyl
- optionally
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261679968P | 2012-08-06 | 2012-08-06 | |
| US61/679,968 | 2012-08-06 | ||
| PCT/EP2013/066388 WO2014023691A1 (en) | 2012-08-06 | 2013-08-05 | Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1210177A1 true HK1210177A1 (en) | 2016-04-15 |
Family
ID=49118489
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15112102.3A HK1211289A1 (en) | 2012-08-06 | 2013-08-05 | Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| HK15111131.0A HK1210177A1 (en) | 2012-08-06 | 2013-08-05 | Dihydroxypyrimidine carbonic acid derivatives and their use in treatment, amelioration or prevention of a viral disease |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15112102.3A HK1211289A1 (en) | 2012-08-06 | 2013-08-05 | Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8921388B2 (enExample) |
| EP (1) | EP2885289A1 (enExample) |
| JP (1) | JP2015524457A (enExample) |
| KR (1) | KR20150039832A (enExample) |
| CN (1) | CN104619699A (enExample) |
| BR (1) | BR112015002516A2 (enExample) |
| CA (1) | CA2879245A1 (enExample) |
| HK (2) | HK1211289A1 (enExample) |
| MX (1) | MX2015001478A (enExample) |
| RU (1) | RU2015107803A (enExample) |
| WO (1) | WO2014023691A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2723746A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| BR112015012454B1 (pt) | 2012-12-07 | 2022-07-05 | Vertex Pharmaceuticals Incorporated | Compostos inibidores de atr quinase, seu uso e composição farmacêutica compreendendo os mesmos |
| WO2014143241A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
| WO2014143242A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| ES2768678T3 (es) | 2013-12-06 | 2020-06-23 | Vertex Pharma | Compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de la ATR quinasa, su preparación, diferentes formas sólidas y derivados radiomarcados de las mismas |
| ES2777608T3 (es) | 2014-06-05 | 2020-08-05 | Vertex Pharma | Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo |
| KR20170016498A (ko) | 2014-06-17 | 2017-02-13 | 버텍스 파마슈티칼스 인코포레이티드 | Chk1 및 atr 저해제의 병용물을 사용하는 암의 치료 방법 |
| CN107074880A (zh) | 2014-07-07 | 2017-08-18 | 萨维拉制药有限公司 | 二氢吡啶并吡嗪‑1,8‑二酮和它们在治疗、改善或预防病毒疾病中的用途 |
| ES2905399T3 (es) * | 2015-04-24 | 2022-04-08 | Shionogi & Co | Derivados heterocíclicos de seis miembros y composición farmacéutica que los comprende |
| RU2712275C9 (ru) | 2015-04-28 | 2020-03-19 | Сионоги Энд Ко., Лтд. | Замещенные полициклические производные пиридона и их пролекарства |
| LT3290424T (lt) | 2015-04-28 | 2023-03-10 | Shionogi & Co., Ltd | Pakeisto policiklinio piridono dariniai ir jo provaistas |
| US20170081331A1 (en) | 2015-09-18 | 2017-03-23 | F. Hoffmann-La Roche Ag | Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease |
| KR102678021B1 (ko) | 2015-09-30 | 2024-06-26 | 버텍스 파마슈티칼스 인코포레이티드 | Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물 |
| US10414735B2 (en) | 2015-11-09 | 2019-09-17 | Forge Therapeutics, Inc. | Substituted hydroxypyrimidinones for treating bacterial infections |
| WO2017083434A1 (en) | 2015-11-09 | 2017-05-18 | Forge Therapeutics, Inc. | Pyrone based compounds for treating bacterial infections |
| BR112018011103A2 (pt) | 2015-12-15 | 2018-11-21 | Shionogi & Co., Ltd. | medicamento para tratar a gripe caracterizada por combinação de inibidor de endonuclease dependente de cap e de fármaco antigripe |
| EP3478671B1 (en) | 2016-06-29 | 2020-05-13 | H. Hoffnabb-La Roche Ag | Pyridazinone-based broad spectrum anti-influenza inhibitors |
| AU2017310774B2 (en) | 2016-08-10 | 2023-01-19 | Shionogi & Co., Ltd. | Substituted polycyclic pyridone derivative and pharmaceutical composition containing prodrug thereof |
| JP6692113B2 (ja) * | 2016-10-21 | 2020-05-13 | 塩野義製薬株式会社 | ６員複素環誘導体を含有する医薬組成物 |
| WO2018208985A2 (en) | 2017-05-10 | 2018-11-15 | Forge Therapeutics, Inc. | Antibacterial compounds |
| JP2020533376A (ja) | 2017-09-15 | 2020-11-19 | アドゥロ バイオテック，インク． | ピラゾロピリミジノン化合物およびその使用 |
| CN109503528B (zh) * | 2018-05-15 | 2022-06-14 | 天津国际生物医药联合研究院 | 一种化合物及其在抗沙粒病毒感染中的应用 |
| CA3113226A1 (en) * | 2018-09-20 | 2020-03-26 | Forge Therapeutics, Inc. | Antibacterial compounds |
| KR20210102310A (ko) | 2018-12-06 | 2021-08-19 | 콘스텔레이션 파마슈티칼스, 인크. | Trex1의 조절인자 |
| CN109897007A (zh) * | 2019-02-25 | 2019-06-18 | 天津国际生物医药联合研究院 | 二羟基嘧啶化合物及其应用 |
| WO2021195260A1 (en) | 2020-03-25 | 2021-09-30 | Forge Therapeutics, Inc. | Lpxc inhibitor and methods of making |
| WO2021195258A1 (en) * | 2020-03-25 | 2021-09-30 | Forge Therapeutics, Inc. | Lpxc inhibitor, formulations, and uses thereof |
| KR20230066379A (ko) | 2020-09-09 | 2023-05-15 | 크리네틱스 파마슈티칼스, 인크. | 소마토스타틴 조절제 제형 |
| PH12023553004A1 (en) * | 2021-05-05 | 2024-03-11 | Constellation Pharmaceuticals Inc | Modulators of trex1 |
| AU2022357226A1 (en) | 2021-09-28 | 2024-05-02 | Blacksmith Medicines, Inc. | Lpxc inhibitors and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5475109A (en) | 1994-10-17 | 1995-12-12 | Merck & Co., Inc. | Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease |
| EP1441735B1 (en) * | 2001-10-26 | 2006-02-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase |
| DE60218511T2 (de) * | 2001-10-26 | 2007-10-25 | Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. | Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase |
| AU2003262946A1 (en) | 2002-08-30 | 2004-03-19 | Pharmacia And Upjohn Company | Method of preventing or treating atherosclerosis or restenosis |
| TW200526635A (en) | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
| KR20060124701A (ko) | 2004-01-12 | 2006-12-05 | 길리애드 사이언시즈, 인코포레이티드 | 피리미딜 포스포네이트 항바이러스성 화합물 및 그의 사용방법 |
| WO2006030807A1 (ja) | 2004-09-15 | 2006-03-23 | Shionogi & Co., Ltd. | Ｈｉｖインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体 |
| TW200716632A (en) | 2005-05-16 | 2007-05-01 | Gilead Sciences Inc | Integrase inhibitor compounds |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| JP5697163B2 (ja) | 2009-03-26 | 2015-04-08 | 塩野義製薬株式会社 | 置換された３−ヒドロキシ−４−ピリドン誘導体 |
| WO2011000566A2 (en) | 2009-06-30 | 2011-01-06 | Savira Pharmaceuticals Gmbh | Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections |
| WO2011046920A1 (en) | 2009-10-12 | 2011-04-21 | Baylor College Of Medicine | Novel dxr inhibitors for antimicrobial therapy |
| US20120329842A1 (en) | 2010-12-23 | 2012-12-27 | Yongcheng Song | Small molecule compounds as broad-spectrum inhibitors of metallo-beta-lactamases |
| US9328075B2 (en) * | 2011-05-05 | 2016-05-03 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for treating influenza |
| CN102617487B (zh) * | 2012-03-02 | 2014-04-02 | 北京工业大学 | 多取代嘧啶酮类化合物及其制备方法和应用 |
| CN102911124B (zh) | 2012-10-25 | 2015-11-25 | 山东大学 | 羟基嘧啶酮类化合物及其制备方法与应用 |
-
2013
- 2013-08-05 BR BR112015002516A patent/BR112015002516A2/pt not_active IP Right Cessation
- 2013-08-05 CA CA2879245A patent/CA2879245A1/en not_active Abandoned
- 2013-08-05 EP EP13759141.8A patent/EP2885289A1/en not_active Withdrawn
- 2013-08-05 HK HK15112102.3A patent/HK1211289A1/xx unknown
- 2013-08-05 CN CN201380041462.1A patent/CN104619699A/zh active Pending
- 2013-08-05 MX MX2015001478A patent/MX2015001478A/es unknown
- 2013-08-05 RU RU2015107803A patent/RU2015107803A/ru not_active Application Discontinuation
- 2013-08-05 JP JP2015525852A patent/JP2015524457A/ja active Pending
- 2013-08-05 KR KR20157005600A patent/KR20150039832A/ko not_active Withdrawn
- 2013-08-05 US US13/958,913 patent/US8921388B2/en not_active Expired - Fee Related
- 2013-08-05 HK HK15111131.0A patent/HK1210177A1/xx unknown
- 2013-08-05 WO PCT/EP2013/066388 patent/WO2014023691A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014023691A1 (en) | 2014-02-13 |
| KR20150039832A (ko) | 2015-04-13 |
| CN104619699A (zh) | 2015-05-13 |
| US20140038990A1 (en) | 2014-02-06 |
| BR112015002516A2 (pt) | 2017-07-04 |
| EP2885289A1 (en) | 2015-06-24 |
| MX2015001478A (es) | 2015-08-12 |
| RU2015107803A (ru) | 2016-09-27 |
| JP2015524457A (ja) | 2015-08-24 |
| CA2879245A1 (en) | 2014-02-13 |
| US8921388B2 (en) | 2014-12-30 |
| HK1211289A1 (en) | 2016-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1210177A1 (en) | Dihydroxypyrimidine carbonic acid derivatives and their use in treatment, amelioration or prevention of a viral disease | |
| EP2864338B1 (en) | 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| EP2794616B1 (en) | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| WO2013174931A1 (en) | 7-oxo-4,7 -dihydro- pyrazolo [1, 5 -a] pyrimidine derivatives which are useful in the treatment, amelioration or prevention of a viral disease | |
| US8952039B2 (en) | Pyridone derivatives and their use in the treatment, ameloriation or prevention of a viral disease | |
| HK1197059A1 (en) | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| US9505758B2 (en) | Substituted 1,5-naphthyridines as endonuclease inhibitors | |
| WO2017046318A1 (en) | Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease | |
| WO2017046362A1 (en) | Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease | |
| CN107001355A (zh) | 吡啶并吡嗪化合物和它们在治疗、改善或预防流感中的用途 | |
| HK1199881B (en) | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| HK1205128B (en) | 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease |